Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/13/2025

Radioactive Iodine Treatment After Thyroidectomy

Risk Stratification and RAI Recommendations

  • The American College of Oncology recommends RAI treatment primarily for intermediate and high-risk patients, while low-risk patients generally do not benefit from routine RAI administration 1, 2
  • For low-risk patients with small (≤1 cm) intrathyroidal differentiated thyroid cancers and no evidence of locoregional metastases, RAI administration is not recommended 2, 3
  • The National Comprehensive Cancer Network recommends considering RAI therapy for intermediate-risk patients, with decision factors including extent of lymph node involvement 1, tumor size, and aggressive histological features 2
  • High-risk patients, including those with gross extrathyroidal extension 4, incomplete tumor resection 3, distant metastases 4, and advanced T3-T4 tumors 1, 4, show significant survival benefits with RAI therapy 2, 3

Monitoring After Treatment

  • The National Comprehensive Cancer Network recommends physical examination, TSH and thyroglobulin measurement with antithyroglobulin antibodies at 6 and 12 months, then annually if disease-free, for patients who received RAI 4, 5
  • Neck ultrasound is the most effective tool for detecting structural disease in the neck, according to the American College of Oncology 3
  • High-sensitivity (<0.2 ng/mL) assays of basal thyroglobulin can be used to verify absence of disease instead of TSH-stimulated thyroglobulin testing, as recommended by the American College of Oncology 1, 3
  • For patients who did not receive RAI, the American College of Radiology recommends a similar follow-up protocol with thyroglobulin monitoring, though interpretation differs due to potential presence of normal thyroid tissue 6

Special Considerations

  • The National Comprehensive Cancer Network recommends considering additional imaging studies before deciding on RAI therapy for patients with biochemical evidence of disease but negative imaging 5
  • Patients with thyroglobulin antibodies require special consideration, as these can interfere with thyroglobulin assays, according to the American College of Oncology 1
  • The trend of thyroglobulin values over time is more valuable than isolated measurements, especially in patients with residual thyroid tissue, as recommended by the American College of Oncology 1

Radioiodine Testing and Treatment in Thyroid Carcinoma Management

Introduction to Radioiodine Testing

  • Radioiodine (131I) is used for both diagnostic testing and therapeutic treatment in differentiated thyroid carcinoma management, as recommended by the National Comprehensive Cancer Network 7, 8
  • Diagnostic whole-body radioiodine scanning (WBS) is performed to detect residual thyroid tissue or metastatic disease after thyroidectomy, according to guidelines from the National Comprehensive Cancer Network and Annals of Oncology 7, 8

Medication Considerations with Radioiodine

  • Guidelines for radioiodine therapy do not list NSAIDs such as diclofenac among medications that interfere with radioiodine uptake or efficacy, as stated by the National Comprehensive Cancer Network 8, 9
  • The primary medication consideration is thyroid hormone management, with TSH suppression using levothyroxine being a key part of treatment, as recommended by the National Comprehensive Cancer Network 8, 10
  • For radioiodine testing and treatment, the focus is on adequate TSH stimulation, which can be achieved either through thyroid hormone withdrawal or recombinant human TSH (rhTSH), according to the National Comprehensive Cancer Network 8, 11

Follow-up and Management

  • Post-testing and treatment follow-up focuses on thyroglobulin measurement, physical examination, and neck ultrasound, as recommended by the National Comprehensive Cancer Network 11
  • Diclofenac and other NSAIDs can be used after radioiodine testing for thyroid carcinoma, without interfering with radioiodine uptake or efficacy, as stated by the Annals of Oncology and the National Comprehensive Cancer Network 7, 8
  • The primary medication considerations after radioiodine testing relate to thyroid hormone management, not pain control medications, according to the National Comprehensive Cancer Network 8, 11

REFERENCES

4

thyroid carcinoma. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

5

thyroid carcinoma. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

6

acr appropriateness criteria<sup>®</sup> thyroid disease. [LINK]

Journal of the American College of Radiology, 2019

8

thyroid carcinoma. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

9

thyroid carcinoma. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

10

thyroid carcinoma. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

11

thyroid carcinoma. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2010